A. Astolfi, C. Bernard, O. Boyer, M. Campo, S. Margaroli et al., Sabine Perrier-Bonnet) We also would like to thank Christian Prad and Nadine Soller for help with patient medical data collection within the Hérault Cancer Registry (Registre des tumeurs de l'Hérault Finally, we are grateful to the EPICAP study group

T. Murez, G. Poinas, L. Cabaniols, M. Robert, and R. Thuret, Pathologists: Drs Didier Brel, Lysiane Schweizer

R. 1. Torre, L. A. , F. Bray, R. L. Siegel, J. Ferlay et al., Global cancer statistics, 2012, Global cancer statistics, pp.87-108, 2012.
DOI : 10.1038/nrc1948

P. Grosclaude, A. Belot, L. Daubisse-marliac, L. Remontet, N. Leone et al., réseau Francim [Prostate cancer incidence and mortality trends in France from, Progres. En. Urol. J, 1980.

F. Balkwill and A. Mantovani, Inflammation and cancer: back to Virchow?, The Lancet, vol.357, issue.9255, pp.539-545, 2001.
DOI : 10.1016/S0140-6736(00)04046-0

L. M. Coussens and Z. Werb, Inflammation and cancer, Nature, vol.2, issue.6917, pp.860-867, 2002.
DOI : 10.1091/mbc.9.4.875

A. Mantovani, P. Allavena, A. Sica, and F. Balkwill, Cancer-related inflammation, Nature, vol.342, issue.7203, pp.436-444, 2008.
DOI : 10.4049/jimmunol.175.2.1197

D. Thapa and R. Ghosh, Chronic inflammatory mediators enhance prostate cancer development and progression, Biochemical Pharmacology, vol.94, issue.2, pp.53-62, 2015.
DOI : 10.1016/j.bcp.2014.12.023

D. Marzo, A. M. , E. A. Platz, S. Sutcliffe, J. Xu et al., Inflammation in prostate carcinogenesis, Nature Reviews Cancer, vol.175, issue.4, pp.256-269, 2007.
DOI : 10.1016/S0002-9440(10)62970-7

B. Gurel, M. S. Lucia, I. M. Thompson, P. J. Goodman, C. M. Tangen et al., Chronic Inflammation in Benign Prostate Tissue Is Associated with High-Grade Prostate Cancer in the Placebo Arm of the Prostate Cancer Prevention Trial, Cancer Epidemiology Biomarkers & Prevention, vol.23, issue.5, pp.847-856, 2014.
DOI : 10.1158/1055-9965.EPI-13-1126

M. J. Thun, S. J. Henley, and C. Patrono, Nonsteroidal Anti-inflammatory Drugs as Anticancer Agents: Mechanistic, Pharmacologic, and Clinical Issues, JNCI Journal of the National Cancer Institute, vol.94, issue.4, pp.252-266, 2002.
DOI : 10.1093/jnci/94.4.252
URL : https://academic.oup.com/jnci/article-pdf/94/4/252/10889556/252.pdf

S. Gupta, M. Srivastava, N. Ahmad, D. G. Bostwick, and H. Mukhtar, Over-expression of cyclooxygenase-2 in human prostate adenocarcinoma, The Prostate, vol.73, issue.20, pp.73-78, 2000.
DOI : 10.1111/j.1464-410X.1994.tb07602.x

P. Patrignani and C. Patrono, Cyclooxygenase inhibitors: From pharmacology to clinical read-outs, Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids, vol.1851, issue.4, 2015.
DOI : 10.1016/j.bbalip.2014.09.016

C. Bosetti, V. Rosato, S. Gallus, J. Cuzick, and C. L. Vecchia, Aspirin and cancer risk: a quantitative review to 2011, Annals of Oncology, vol.23, issue.6, pp.1403-1415, 2012.
DOI : 10.1093/annonc/mds113
URL : https://academic.oup.com/annonc/article-pdf/23/6/1403/13786139/mds113.pdf

C. Bosetti, V. Rosato, S. Gallus, and C. L. Vecchia, Aspirin and Prostate Cancer Prevention, Recent Results Cancer Res, vol.202, pp.93-100, 2014.
DOI : 10.1007/978-3-642-45195-9_11

S. M. Mahmud, E. L. Franco, and A. G. Aprikian, Use of nonsteroidal anti-inflammatory drugs and prostate cancer risk: A meta-analysis, International Journal of Cancer, vol.83, issue.7, pp.1680-1691, 2010.
DOI : 10.1016/0092-8674(95)90127-2

Y. Liu, J. Chen, L. Xie, J. Wang, T. Li et al., Effect of aspirin and other non-steroidal anti-inflammatory drugs on prostate cancer incidence and mortality: a systematic review and meta-analysis, BMC Medicine, vol.127, issue.1, 2014.
DOI : 10.1007/s004320000225

X. Wang, Y. Lin, J. Wu, Y. Zhu, X. Xu et al., Meta-analysis of nonsteroidal anti-inflammatory drug intake and prostate cancer risk, World Journal of Surgical Oncology, vol.12, issue.1, p.304, 2014.
DOI : 10.1001/jama.283.15.2008

T. Huang, Y. Yan, Z. Guo, X. Zhang, H. Liu et al., Aspirin use and the risk of prostate cancer: a meta-analysis of 24 epidemiologic studies, International Urology and Nephrology, vol.19, issue.9, pp.1715-1728, 2014.
DOI : 10.1002/ijc.28423

L. A. García-rodríguez and A. González-pérez, Inverse association between nonsteroidal antiinflammatory drugs and prostate cancer, Cancer Epidemiol. Biomark. Prev, vol.13, pp.649-653, 2004.

A. S. Murad, L. Down, G. D. Smith, J. L. Donovan, J. A. Lane et al., Associations of aspirin, nonsteroidal anti-inflammatory drug and paracetamol use with PSA-detected prostate cancer: Findings from a large, population-based, case-control study (the ProtecT study), International Journal of Cancer, vol.53, issue.6, pp.1442-1448, 2011.
DOI : 10.1016/j.eururo.2007.08.034

T. Veitonmäki, T. J. Murtola, L. Määttänen, K. Taari, U. Stenman et al., Prostate cancer risk and nonsteroidal antiinflammatory drug use in the Finnish prostate cancer screening trial, British Journal of Cancer, vol.11, issue.7, pp.1421-1431, 2014.
DOI : 10.1002/1097-0142(20000801)89:3<589::AID-CNCR14>3.0.CO;2-C

K. Dasgupta, D. Di-cesar, J. Ghosn, R. Rajan, S. Mahmud et al., Association between nonsteroidal anti-inflammatory drugs and prostate cancer occurrence, Cancer J, vol.12, pp.130-135, 2006.

E. J. Jacobs, C. Rodriguez, A. M. Mondul, C. J. Connell, S. J. Henley et al., A Large Cohort Study of Aspirin and Other Nonsteroidal Anti-inflammatory Drugs and Prostate Cancer Incidence, JNCI: Journal of the National Cancer Institute, vol.97, issue.13, pp.975-980, 2005.
DOI : 10.1093/jnci/dji173

S. M. Mahmud, E. L. Franco, D. Turner, R. W. Platt, P. Beck et al., Use of Non-Steroidal Anti-Inflammatory Drugs and Prostate Cancer Risk: A Population-Based Nested Case-Control Study, PLoS ONE, vol.94, issue.1, p.16412, 2011.
DOI : 10.1371/journal.pone.0016412.t006

E. A. Platz, S. Rohrmann, J. D. Pearson, M. M. Corrada, D. J. Watson et al., Nonsteroidal Anti-inflammatory Drugs and Risk of Prostate Cancer in the Baltimore Longitudinal Study of Aging, Cancer Epidemiology Biomarkers & Prevention, vol.14, issue.2, pp.390-396, 2005.
DOI : 10.1158/1055-9965.EPI-04-0532

T. M. Brasky, C. M. Velicer, A. R. Kristal, U. Peters, J. D. Potter et al., Nonsteroidal Anti-Inflammatory Drugs and Prostate Cancer Risk in the VITamins And Lifestyle (VITAL) Cohort, Cancer Epidemiology Biomarkers & Prevention, vol.19, issue.12, pp.3185-3188, 2010.
DOI : 10.1158/1055-9965.EPI-10-0942

L. Perron, I. Bairati, L. Moore, and F. Meyer, Dosage, duration and timing of nonsteroidal antiinflammatory drug use and risk of prostate cancer, International Journal of Cancer, vol.333, issue.3, pp.409-415, 2003.
DOI : 10.1002/ijc.11250

C. A. Salinas, E. M. Kwon, L. M. Fitzgerald, Z. Feng, P. S. Nelson et al., Use of Aspirin and Other Nonsteroidal Antiinflammatory Medications in Relation to Prostate Cancer Risk, American Journal of Epidemiology, vol.172, issue.5, pp.578-590, 2010.
DOI : 10.1093/aje/kwq175

A. C. Vidal, L. E. Howard, D. M. Moreira, R. Castro-santamaria, G. L. Andriole et al., Aspirin, NSAIDs, and Risk of Prostate Cancer: Results from the REDUCE Study, Clinical Cancer Research, vol.21, issue.4, pp.756-762, 2015.
DOI : 10.1158/1078-0432.CCR-14-2235

S. Jafari, M. Etminan, and K. Afshar, Nonsteroidal anti-inflammatory drugs and prostate cancer: a systematic review of the literature and meta-analysis, Canadian Urological Association Journal, vol.3, issue.4, pp.323-330, 2009.
DOI : 10.5489/cuaj.1129

F. Menegaux, A. Anger, H. Randrianasolo, C. Mulot, P. Laurent-puig et al., Epidemiological study of prostate cancer (EPICAP): a population-based case???control study in France, BMC Cancer, vol.2, issue.Suppl 2, p.106, 2014.
DOI : 10.1158/2159-8290.CD-12-0424
URL : https://hal.archives-ouvertes.fr/inserm-00952941

R. Des, T. De-l-'herault, and . Internet, Available at http://www.registre-tumeurs-herault.fr, 2017.

J. A. Baron, B. F. Cole, R. S. Sandler, R. W. Haile, D. Ahnen et al., A Randomized Trial of Aspirin to Prevent Colorectal Adenomas, New England Journal of Medicine, vol.348, issue.10, pp.891-899, 2003.
DOI : 10.1056/NEJMoa021735

N. Arber, J. Spicak, I. Rácz, M. Zavoral, A. Breazna et al., Five-Year Analysis of the Prevention of Colorectal Sporadic Adenomatous Polyps Trial, The American Journal of Gastroenterology, vol.134, issue.6, pp.1135-1146, 2011.
DOI : 10.1053/j.gastro.2008.02.012

M. M. Bertagnolli, C. J. Eagle, A. G. Zauber, M. Redston, A. Breazna et al., Five-Year Efficacy and Safety Analysis of the Adenoma Prevention with Celecoxib Trial, Cancer Prevention Research, vol.2, issue.4, pp.310-321, 2009.
DOI : 10.1158/1940-6207.CAPR-08-0206

C. Skriver, C. Dehlendorff, M. Borre, K. Brasso, H. T. Sørensen et al., Low-dose aspirin or other nonsteroidal anti-inflammatory drug use and prostate cancer risk: a nationwide study, Cancer Causes & Control, vol.52, issue.9, pp.1067-1079, 2016.
DOI : 10.3109/0284186X.2012.702922

E. J. Jacobs, M. J. Thun, E. B. Bain, C. Rodriguez, S. J. Henley et al., A Large Cohort Study of Long-Term Daily Use of Adult-Strength Aspirin and Cancer Incidence, JNCI Journal of the National Cancer Institute, vol.99, issue.8, pp.608-615, 2007.
DOI : 10.1093/jnci/djk132

T. Veitonmäki, T. L. Tammela, A. Auvinen, and T. J. Murtola, Use of aspirin, but not other non-steroidal anti-inflammatory drugs is associated with decreased prostate cancer risk at the population level, European Journal of Cancer, vol.49, issue.4, pp.938-945, 1990.
DOI : 10.1016/j.ejca.2012.09.030

Y. Vinogradova, C. Coupland, and J. Hippisley-cox, Exposure to cyclooxygenase-2 inhibitors and risk of cancer: nested case???control studies, British Journal of Cancer, vol.311, issue.3, pp.452-459, 2011.
DOI : 10.1158/1940-6207.CAPR-09-0181

R. E. Harris, J. Beebe-donk, and G. A. Alshafie, Cancer Chemoprevention by Cyclooxygenase 2 (COX-2) Blockade, Subcell. Biochem, vol.42, pp.193-212, 2007.
DOI : 10.1007/1-4020-5688-5_9

J. Font-burgada, M. Sun, and . Karin, Obesity and Cancer: The Oil that Feeds the Flame, Cell Metabolism, vol.23, issue.1, pp.48-62, 2016.
DOI : 10.1016/j.cmet.2015.12.015

K. Boehm, R. Valdivieso, M. Meskawi, A. Larcher, J. Schiffmann et al., Prostatitis, other genitourinary infections and prostate cancer: results from a population-based case???control study, World Journal of Urology, vol.40, issue.5, pp.425-430, 2016.
DOI : 10.1159/000049840
URL : https://hal.archives-ouvertes.fr/pasteur-01350845